Cocrystal Pharma To Highlight Near-term Clinical Milestones During Presentations At Two Upcoming Investment Conferences

Cocrystal Pharma, Inc.'s (NASDAQ:COCP) management announces its participation in the upcoming Virtual Investor Summit Microcap Forum in August and the H.C. Wainwright 26th Annual Global Investment Conference in September.

 

"We look forward to showcasing key near-term clinical milestones at two upcoming investment conferences," said James Martin, CFO and co-CEO of Cocrystal. "We expect to report topline results in 2024 from our influenza A Phase 2a challenge study with our novel oral PB2 inhibitor CC-42344 with the final report expected to be filed in 2025. We also expect to report topline results from the Phase 1 multiple-ascending cohorts in late 2024 or early 2025 with our novel oral protease inhibitor CDI-988 for the treatment of norovirus and coronavirus infections."